CorriXR Therapeutics Partners to Develop First Inhaled CRISPR Therapy for Lung Cancer
核心洞察
CorriXR Therapeutics (搜索) has launched a strategic collaboration with InhaTarget Therapeutics (搜索) and Merxin Ltd (搜索) to develop the first inhaled CRISPR-based genetic therapy for lung cancer treatment.
The therapy targets NRF2 (搜索), a key driver of treatment resistance in squamous cell lung carcinoma, with preclinical data showing it can resensitize tumors to chemotherapy with minimal off-target effects.
The innovative approach combines CorriXR's CRISPR gene editing platform with InhaTarget's lipid nanoparticle formulation and Merxin's advanced inhaler technology for direct lung tumor delivery.
CorriXR Therapeutics (搜索), ChristianaCare (搜索)'s first commercial biotherapeutics spinout, has announced a groundbreaking strategic collaboration with InhaTarget Therapeutics (搜索) and Merxin Ltd (搜索) to develop the world's first inhaled CRISPR-based genetic therapy for lung cancer. The partnership aims to deliver targeted treatment directly to lung tumors while minimizing systemic side effects for patients facing one of the deadliest cancers globally.
Targeting Treatment Resistance with CRISPR Technology
The innovative therapeutic approach centers on CorriXR's proprietary CRISPR-based gene editing platform that targets NRF2 (搜索), a transcription factor controlling more than 200 genes that create a pro-oncogenic tumor microenvironment and drive treatment resistance. According to research published in Molecular Therapy Oncology, preclinical data in lung cancer models demonstrated that disabling NRF2 can meaningfully resensitize tumor response to chemotherapy with minimal off-target effects.
"This partnership represents a significant step forward in our mission to harness the power of CRISPR-based gene editing for the benefit of patients with cancer by slowing the growth of solid tumors and improving effectiveness of existing treatments," said Dr. Eric B. Kmiec, founder and CEO of CorriXR Therapeutics (搜索) and chief scientific officer at ChristianaCare (搜索)'s Gene Editing Institute.
Addressing Critical Unmet Medical Need
The collaboration specifically targets squamous cell lung carcinoma (LUSC), an aggressive form of non-small cell lung cancer that comprises 25-30% of worldwide cases. With over 380,000 new cases of LUSC diagnosed globally each year and a five-year survival rate below 15%, the need for new therapies is urgent. Current standard treatments of chemotherapy plus immunotherapy or immunotherapy alone typically result in progression after 8 months or less, with many patients developing treatment resistance that leaves limited options beyond dose escalation.
Revolutionary Inhaled Delivery System
The treatment will be administered through inhalation using InhaTarget's proprietary lipid nanoparticle (LNP) formulation platform combined with Merxin Ltd (搜索)'s advanced inhaler device technology. This approach enables encapsulation of active ingredients for direct delivery to lung tumors, potentially offering a non-invasive therapy that patients could use at home.
"Combining our pulmonary drug delivery LNP platform with CorriXR's groundbreaking science and Merxin's device technology has the potential to reshape the landscape of lung cancer treatment," said Dr. Frédéric De Coninck, co-founder and CEO of InhaTarget Therapeutics (搜索).
Merxin Ltd (搜索)'s contribution involves adapting their patented inhaler technology to handle lipid nanoparticle formulations for the first time in a cancer treatment application. "Our advanced inhaler technology is designed to ensure non-invasive, precise, consistent delivery of novel therapeutics," explained Dr. Philippe Rogueda, co-founder and chief business officer of Merxin Ltd.
Clinical Development Timeline
Initial studies will be conducted in cell culture and in a lung carcinoma mouse model, with substantial results on effectiveness and impact expected by spring 2026. The collaboration seeks to demonstrate effective delivery of the CorriXR compound via InhaTarget's LNP formulation platform, with results anticipated by mid-2026.
"This collaboration underscores the power of combining innovative science with practical delivery solutions," Kmiec noted. "Our CRISPR-based approach is designed to overcome one of the toughest challenges in oncology: treatment resistance. By partnering with experts in inhalation technology, we are moving closer to a therapy that is not only effective but accessible."
The partnership represents a significant advancement in precision oncology, potentially offering lung cancer patients a treatment option that maximizes efficacy while minimizing the systemic toxicity associated with traditional chemotherapy approaches.